{"id":10681,"date":"2026-02-23T23:02:30","date_gmt":"2026-02-23T23:02:30","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2026\/02\/23\/bayer-jnj-prostate-cancer-false-advertising-lawsuit\/"},"modified":"2026-02-23T23:02:30","modified_gmt":"2026-02-23T23:02:30","slug":"bayer-jnj-prostate-cancer-false-advertising-lawsuit","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2026\/02\/23\/bayer-jnj-prostate-cancer-false-advertising-lawsuit\/","title":{"rendered":"STAT+: Bayer sues J&J over \u2018false and misleading claims\u2019 about competing prostate cancer treatments"},"content":{"rendered":"\n
STAT+: Bayer sues J&J over \u2018false and misleading claims\u2019 about competing prostate cancer treatments<\/div>\n

\t

\n
<\/BR>
\n
\n \t

\n
<\/BR><\/p>\n

\n

Underscoring the high-stakes market for prostate cancer medicines, Bayer filed a lawsuit accusing Johnson & Johnson of launching a \u201cfalse advertising campaign\u201d that uses flawed data to wrongfully promote its rival drug as a more effective treatment.<\/p>\n

At issue are claims J&J made in a Feb. 2 press release, as well as in presentations on its website, about its Erleada prostate cancer drug in comparison with a Bayer medication called Nubeqa. Both drugs are androgen receptor inhibitors that can prevent the growth of cancer cells and are frequently combined with other treatments.<\/p>\n

It was only last June that Bayer won U.S. regulatory approval to market its drug in combination with androgen deprivation therapy, posing new competition for the J&J drug. This prompted J&J to promote its medication as a superior choice in the press release and on two website slide presentations aimed at physicians, the lawsuit<\/a> stated.<\/p>\n

Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n

\t

\n
<\/BR>
\n Ed Silverman
\n \t

\n
<\/BR>
\nGo to statnews<\/a>
\n \t

\n
<\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"

STAT+: Bayer sues J&J over \u2018false and misleading claims\u2019 about competing prostate cancer treatments Underscoring the high-stakes market for prostate cancer medicines, Bayer filed a lawsuit accusing Johnson & Johnson of launching a \u201cfalse advertising campaign\u201d that uses flawed data to wrongfully promote its rival drug as a more effective treatment. At issue are claims […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2159,4113,2155,2153,2152],"tags":[2150],"class_list":["post-10681","post","type-post","status-publish","format-standard","hentry","category-cancer","category-johnson-johnson","category-pharmaceuticals","category-pharmalot","category-stat","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/10681"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=10681"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/10681\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=10681"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=10681"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=10681"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}